Global Epigenomics Market Report and Forecast 2024-2032

Global Epigenomics Market Outlook

The global epigenomics market is expected to grow at a CAGR of 13.1% during the forecast period of 2024-2032, driven by the rising prevalence of chronic diseases and genetic conditions, and the increasing need for research and development to explore enhanced treatment alternatives for diseases and conditions.

Modern techniques enable scientists to study epigenetic changes across entire genomes and determine how and where such changes occur. Scientists seek a better understanding of the occurrence of epigenetic changes and their consequences. Further, by identifying patterns of methylation tags across the whole genome and of histone modifications in various kinds of cells and tissues, it would be possible for scientists to recognize "signatures" associated with certain biological processes or disease states. North America, Europe and Asia are expected to be key markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by the Need to Study Complex Diseases

Epigenomics refers to the study of the epigenome – a host of chemical compounds directing the functioning genome as a whole. These compounds attach to the DNA to activate or deactivate particular genes in the genome, changing its behaviour. Thus, the epigenome may influence regulation of protein production in some cells of the body. Researchers monitor locations and understand the functions of all the chemical tags marking the genome. When epigenomic compounds bind to DNA and alter its function, it is said that these compounds have "marked" the genome. While these marks do not change the DNA sequence, they alter the way cells use the DNA's instructions. The marks are occasionally passed on from cell to cell as cells divide. These also can be passed down from generation to generation.

There are trillion of cells in a human being; these cells have specific functions in the muscles, bones and brain, and each cell contains fundamentally the same genome in its nucleus. The way and when the different gene sets are turned on or off in different types of cells determine differences among cells. For example, specific cells in the eye turn on genes producing proteins that may detect light; particular cells in red blood cells produce proteins carrying oxygen from the air to the rest of the body. The epigenome regulates several of these changes to the genome. The epigenome is the group of chemical modifications to the DNA and DNA-associated proteins in the cell, altering gene behaviour, and are heritable (through meiosis and mitosis). The modifications take place as a natural process of development and tissue differentiation, and may be changed in response to environmental exposures or disease.

The first type of mark, known as DNA methylation, directly influences the DNA in a genome. In the process, proteins bind chemical tags called methyl groups to the bases of the DNA molecule in particular places. The methyl groups turn genes on or off by influencing interactions between the DNA and other proteins. Thus, cells can remember which genes are on or off. The second type of mark, called histone modification, influences DNA indirectly. DNA in cells is wrapped around histone proteins, forming spool-like structures enabling DNA's very long molecules to be coiled up neatly into chromosomes within the cell nucleus. Proteins can bind several chemical tags to histones. Other proteins in cells can identify these tags and decide whether that region of DNA should be used or ignored in the cell.

Lifestyle and environmental factors (which include smoking, diet and infectious disease) could expose an individual to pressures that induce chemical responses. These responses, in turn, could cause changes in the epigenome; some changes could be damaging. Cancers could be caused by changes in the genome, the epigenome, or both. Changes in the epigenome could switch on or off genes engaged in cell growth or the immune response, causing uncontrolled growth (a sign of cancer), or leading to a failure of the immune system to destroy tumours.

In cases of glioblastoma (a kind of brain tumour), the drug temozolomide has been used with some success; the drug kills cancer cells by attaching methyl groups to DNA. In some cases, methylation shows another positive – it blocks a gene that counteracts temozolomide. Patients with glioblastoma who have tumours with such methylated genes are more likely to respond to temozolomide as compared to those with unmethylated genes. Changes in the epigenome could also trigger growth-promoting genes in colon cancer, stomach cancer, and the most common type of kidney cancer. In some other types of cancer, changes in the epigenome stifle genes that generally help regulate cell growth.

Several research groups are engaged in an attempt to characterize the epigenome, and recognize, catalogue, and understand genome-wide DNA methylation patterns of all human genes in all key tissues. Such associations are multinational and multidisciplinary, and characterize the highest quality of research. Epigenomics, as a domain, has the potential to examine and reveal nongenetic components of complex diseases. It is hoped that with full genome sequence and epigenomic maps of the DNA methylation and modified histone landscapes, it would be possible to identify the exact genes that activated, and in which tissues. Such information would provide new ways to diagnose and treat complex diseases, and is expected to drive the global epigenomics market.

Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By technology, the global epigenomics market is segmented into:

• Histone Methylation
• Large Non-Coding RNA
• MicroRNA Modification
• DNA Methylation
• Chromatin Structures
• Others

By product type, the market is divided into:

• Kits
• Reagents
• Enzymes
• Others

By application, the market is classified into:

• Diagnostics
• Pharmaceuticals

By region, the market is segmented into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global epigenomics market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Epigenomics AG

• Illumina, Inc.

• Merck KGaA

• Zymo Research Corporation

• Agilent Technologies, Inc.

• Thermo Fisher Scientific

• PacBio (US)

• Abcam plc (UK)

• Bio-Rad Laboratories

• Novartis AG

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report